Interview With Samantha Shenoy, MSN, ACNP-BC: Navigating New Frontiers in CAR-T and Cellular Therapies

Interview With Samantha Shenoy, MSN, ACNP-BC: Evolving Clinical Models for CAR-T and Bispecific Antibodies in Multiple Myeloma

Interview With Justina Kiernan, PA-C: Advancing Myeloma Care–New Strategies for Relapsed Disease Management

View all

Welcome to the Multiple Myeloma Resource Center! Here you’ll find current information, news items, highlights from the literature, and other resources that focus on multiple myeloma and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Charise Gleason, MSN, NP-C, AOCNP Winship Cancer Institute of Emory University Nell Hodgson Woodruff School of Nursing at Emory Healthcare	Amy Pierre, MSN, RN, ANP-BC Memorial Sloan Kettering Cancer Center Myeloma/Lymphoma Division Flatiron Health Real World Evidence Research Oncology

Dietary and Microbiome Evidence in Multiple Myeloma and Other Plasma Cell Disorders

Make it Happen: To Better Serve the Multiple Myeloma Community

Role of the Clinical Pharmacist in Multiple Myeloma Management

International Myeloma Working Group Immunotherapy Committee Consensus Guidelines and Recommendations for Optimal Use of T-Cell-Engaging Bispecific Antibodies In Multiple Myeloma

Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit

Molecular and Cellular Probes

The role of RNA modifications in the pathological mechanisms and therapeutic targeting of multiple myeloma

Cancer Epidemiology

Occupational pesticide exposure and association of monoclonal gammopathy of undetermined significance in the Western Macroregion of Paraná

American Journal of Blood Research

Therapy-related B-cell acute lymphoblastic leukemia after treatment for multiple myeloma

The Lancet

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

The Asco Post

Off-the-shelf CAR T-cell therapy produces deep, durable responses in heavily pretreated multiple myeloma

Journal of Translational Medicine

Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma with extramedullary disease

Transplantation and Cellular Therapy

Trial in progress: QUINTESSENTIAL-2—a phase 3 Study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

The FEBS Journal

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

Cancer Medicine

Lenalidomide plus dexamethasone as first-line therapy in transplant-ineligible patients with multiple myeloma

American Journal of Hematology

The role of bispecific antibodies in relapsed/refractory multiple myeloma with renal impairment: A systematic review

Multiple Myeloma Resource Center